| [1] |
Beuers U, Gershwin ME, Gish RG, et al. Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'. Gut, 2015, 64: 1671-1672.
|
| [2] |
Beuers U, Gershwin ME, Gish RG, et al. Changing Nomenclature for PBC: From 'Cirrhosis' to 'Cholangitis'. Am J Gastroenterol, 2015, 110: 1536-1538.
|
| [3] |
Beuers U, Gershwin ME, Gish RG, et al. Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'. J Hepatol, 2015, 63: 1285-1287.
|
| [4] |
Beuers U, Gershwin ME, Gish RG, et al. Changing nomenclature for PBC: from 'cirrhosis' to 'cholangitis'. Gastroenterology, 2015, 149: 1627-1629.
|
| [5] |
Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet, 2015, 386: 1565-1575.
|
| [6] |
Mousa HS, Lleo A, Invernizzi P, et al. Advances in pharmacotherapy for primary biliary cirrhosis. Expert Opin Pharmacother, 2015, 16: 633-643.
|
| [7] |
Nakamura M. Clinical significance of autoantibodies in primary biliary cirrhosis. Semin Liver Dis, 2014, 34: 334-340.
|
| [8] |
Wang L, Wang FS, Chang C, et al. Breach of tolerance: primary biliary cirrhosis. Semin Liver Dis, 2014, 34: 297-317.
|
| [9] |
Dhanda A, Lee R, Collins P. Is primary biliary cirrhosis a steroid-sensitive autoimmune disease. Hepatol Res, 2012, 42: 619-620.
|
| [10] |
Kar SP, Seldin MF, Chen W, et al. Pathway-based analysis of primary biliary cirrhosis genome-wide association studies. Genes Immun, 2013, 14: 179-186.
|
| [11] |
Carbone M, Lleo A, Sandford RN, et al. Implications of genome-wide association studies in novel therapeutics in primary biliary cirrhosis. Eur J Immunol, 2014, 44: 945-954.
|
| [12] |
Hirschfield GM, Gershwin ME, Strauss R, et al. Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid: A proof-of-concept study. Hepatology, 2016,64:189-199.
|
| [13] |
Huang Q, Shao F, Wang C, et al. Association between CTLA-4 exon-1 +49A>G polymorphism and primary biliary cirrhosis risk: a meta-analysis. Arch Med Res, 2011,42:235-238.
|
| [14] |
Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev, 2010,236:219-242.
|
| [15] |
Okwor I, Jia P, Uzonna JE. Interaction of Macrophage Antigen 1 and CD40 Ligand Leads to IL-12 Production and Resistance in CD40-Deficient Mice Infected with Leishmania major. J Immunol, 2015,195:3218-3226.
|
| [16] |
Humphreys EH, Williams KT, Adams DH, et al. Primary and malignant cholangiocytes undergo CD40 mediated Fas dependent apoptosis, but are insensitive to direct activation with exogenous Fas ligand. PLoS One, 2010,5:e14037.
|
| [17] |
Bernuzzi F, Fenoglio D, Battaglia F, et al. Phenotypical and functional alterations of CD8 regulatory T cells in primary biliary cirrhosis. J Autoimmun, 2010,35:176-180.
|
| [18] |
Sharma R, Fu SM, Ju ST. IL-2: a two-faced master regulator of autoimmunity. J Autoimmun, 2011,36:91-97.
|
| [19] |
Singer BD, King LS, D'Alessio FR. Regulatory T cells as immunotherapy. Front Immunol, 2014,5:46.
|
| [20] |
Myers RP, Swain MG, Lee SS, et al. B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol, 2013,108:933-941.
|
| [21] |
Allen K, Jaeschke H, Copple BL. Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol, 2011,178:175-186.
|
| [22] |
de Aguiar Vallim TQ, Tarling EJ, Ahn H, et al. MAFG is a transcriptional repressor of bile acid synthesis and metabolism. Cell Metab, 2015,21:298-310.
|
| [23] |
Hollman DA, Milona A, van Erpecum KJ, et al. Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms. Biochim Biophys Acta, 2012,1821:1443-1452.
|
| [24] |
Hirschfield GM, Mason A, Luketic V, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology, 2015,148:751-761.e8.
|
| [25] |
Wagner M, Halilbasic E, Marschall HU, et al. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. Hepatology, 2005,42:420-430.
|
| [26] |
Wang N, Li P, Wang Y, et al. Hepatoprotective effect of Hypericum japonicum extract and its fractions. J Ethnopharmacol, 2008,116:1-6.
|
| [27] |
Guo C, Qi H, Yu Y, et al. The G-Protein-Coupled Bile Acid Receptor Gpbar1 (TGR5) Inhibits Gastric Inflammation Through Antagonizing NF-κB Signaling Pathway. Front Pharmacol, 2015,6:287.
|
| [28] |
Péan N, Doignon I, Garcin I, et al. The receptor TGR5 protects the liver from bile acid overload during liver regeneration in mice. Hepatology, 2013,58:1451-1460.
|
| [29] |
Zhang JH, Nolan JD, Kennie SL, et al. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. Am J Physiol Gastrointest Liver Physiol, 2013,304:G940-948.
|
| [30] |
Poupon R. ASBT inhibitors in cholangiopathies - Good for mice, good for men. J Hepatol, 2016,64:537-538.
|
| [31] |
Hohenester S, Wenniger LM, Paulusma CC, et al. A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology, 2012,55:173-183.
|
| [32] |
Trauner M, Halilbasic E, Claudel T, et al. Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders. Dig Dis, 2015,33:433-439.
|
| [33] |
Kohjima M, Enjoji M, Yada R, et al. Pathophysiological analysis of primary biliary cirrhosis focusing on choline/phospholipid metabolism. Liver Int, 2015,35:1095-1102.
|
| [34] |
Hosonuma K, Sato K, Yamazaki Y, et al. A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol, 2015,110:423-431.
|
| [35] |
Pellicoro A, Ramachandran P, Iredale JP, et al. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol, 2014,14:181-194.
|
| [36] |
Inamine T, Nakamura M, Kawauchi A, et al. A polymorphism in the integrin αV subunit gene affects the progression of primary biliary cirrhosis in Japanese patients. J Gastroenterol, 2011,46:676-686.
|
| [37] |
Mazza G, De Coppi P, Gissen P, et al. Hepatic regenerative medicine. J Hepatol, 2015,63:523-524.
|
| [38] |
Christensen E, Gunson B, Neuberger J. Optimal timing of liver transplantation for patients with primary biliary cirrhosis: use of prognostic modelling. J Hepatol, 1999,30:285-292.
|
| [39] |
EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol, 2009,51:237-267.
|
| [40] |
Singal AK, Fang X, Kaif M, et al. Primary biliary cirrhosis has high wait-list mortality among patients listed for liver transplantation. Transpl Int, 2016.
|
